Physician profile
Fares Hamad
NPI 1275831521
$2,902.74
in general payments reported to CMS, 2019-2025
12 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2021: $139 · 2022: $458 · 2023: $281 · 2024: $576 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198 · Travel and Lodging: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.67 |
| Travel and Lodging | $750.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,069.70 | 2019-2025 | Overstitch Endoscopic Suturing System, Exalt Model D, Apollo 2-0 Polypropylene Endobariatric Suture |
| Medtronic, INC. | $175.00 | 2022 | |
| Endogastric Solutions, INC | $158.38 | 2022-2023 | Esophyx |
| Abbvie INC. | $111.37 | 2021-2024 | |
| Apollo Endosurgery US INC | $106.82 | 2023 | Overstitch Endoscopic Suturing System |
| Ironwood Pharmaceuticals, INC | $97.45 | 2019 | |
| Olympus America INC. | $90.83 | 2021 | |
| Mauna Kea Technologies, INC. | $37.01 | 2019-2023 | |
| Janssen Biotech, INC. | $20.75 | 2024 | Stelara, Simponi Aria, Tremfya |
| Braintree Laboratories, INC. | $15.26 | 2023 | Sutab |
| Hologic Sales and Service, LLC | $15.16 | 2024 | Aptima |
| Echosens North America, INC. | $5.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fares Hamad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.